Ekso Bionics

Worldwide Artificial Organ and Bionics Industry to 2025 - Advantageous in Comparison Prosthetics Presents Opportunities

Tuesday, April 13, 2021 - 7:15pm

This has been a major boost for the artificial organ bionics market, as the patients cannot afford to wait in queue since the stakes are very high.

Key Points: 
  • This has been a major boost for the artificial organ bionics market, as the patients cannot afford to wait in queue since the stakes are very high.
  • Bionics and artificial organs are able to cater to the needs of those in need of organ transplantations and replacements.
  • In February 2020, Ekso Bionics Holdings, Inc. collaborated with Kindred Healthcare, LLC to pilot EksoNR - a robotic exoskeleton, in their long-term acute care hospitals.\n2.
  • In April 2019, Edwards Lifesciences Corporation acquired CAS Medical Systems, Inc., a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring.\n3.

Global Artificial Organ and Bionics Market (2020 to 2025) - by Type, Technology, End-user and Geography - ResearchAndMarkets.com

Thursday, April 8, 2021 - 1:48pm

In February 2020, Ekso Bionics Holdings, Inc. collaborated with Kindred Healthcare, LLC to pilot EksoNR - a robotic exoskeleton, in their long-term acute care hospitals.

Key Points: 
  • In February 2020, Ekso Bionics Holdings, Inc. collaborated with Kindred Healthcare, LLC to pilot EksoNR - a robotic exoskeleton, in their long-term acute care hospitals.
  • In April 2019, Edwards Lifesciences Corporation acquired CAS Medical Systems, Inc., a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring.
  • The report offers a comprehensive evaluation of the Global Artificial Organ and Bionics Market.
  • The report also contains the competitive analysis using IGR Competitive Quadrant, the analyst's proprietary competitive positioning tool.

Ekso Bionics Announces Partnership with U.S. Physiatry to Support Physician Education of EksoNR

Tuesday, March 9, 2021 - 1:00pm

The partnership will help expand awareness of Ekso Bionics technology among physicians and other rehabilitation clinicians as well as educate on how to successfully implement robotics into a rehabilitation program.

Key Points: 
  • The partnership will help expand awareness of Ekso Bionics technology among physicians and other rehabilitation clinicians as well as educate on how to successfully implement robotics into a rehabilitation program.
  • Topics will include EksoNR education, research and development, best practices on Ekso program implementation, and general marketing of an EksoNR.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.
  • To learn more about Ekso Bionics please visit the Companys website at www.eksobionics.com or follow @EksoBionics on Twitter.

Ekso Bionics Teams Up with Performance Contracting, Inc. for Innovative Testing Approach of EVO™ Technology

Wednesday, March 3, 2021 - 1:00pm

Over the course of a year, PCI employees in six Bay Area counties have committed to testing EVO exoskeleton vests for the Companys continued product development and innovation.

Key Points: 
  • Over the course of a year, PCI employees in six Bay Area counties have committed to testing EVO exoskeleton vests for the Companys continued product development and innovation.
  • We are excited that PCIs workforce will benefit from our novel EVO technology, commented Michael Pratt, Vice President of Ekso Bionics.
  • Companies within the construction vertical are starting to recognize that EVO provides meaningful support for workers when performing routine and labor-intensive tasks.
  • To learn more about Ekso Bionics please visit the Companys website at www.eksobionics.com or follow @EksoBionics on Twitter.

Ekso Bionics to Present at the H.C. Wainwright Global Life Sciences Conference

Tuesday, March 2, 2021 - 1:00pm

RICHMOND, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that Jack Glenn, Chief Financial Officer, will present at the H.C. Wainwright Global Life Sciences Conference held on March 9 10, 2021.

Key Points: 
  • RICHMOND, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that Jack Glenn, Chief Financial Officer, will present at the H.C. Wainwright Global Life Sciences Conference held on March 9 10, 2021.
  • Ekso Bionicsis a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications.
  • Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe.
  • The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Ekso Bionics Reports Fourth Quarter and Year End 2020 Results

Thursday, February 25, 2021 - 9:05pm

Revenue was $2.3 million for the quarter ended December 31, 2020, compared to $3.7 million for the same period in 2019.

Key Points: 
  • Revenue was $2.3 million for the quarter ended December 31, 2020, compared to $3.7 million for the same period in 2019.
  • Revenue in the fourth quarter of 2020 included approximately $2.1 million in EksoHealth revenue and approximately $0.2 million in EksoWorks revenue.
  • The Company booked a total of 14 EksoNR units in the fourth quarter of 2020, including 4 subscription units.
  • To learn more about Ekso Bionics please visit the Companys website at www.eksobionics.com or refer to the Companys Twitter page at @EksoBionics.

ReWalk Robotics Announces $40.0 Million Private Placement Priced At-the-Market

Friday, February 19, 2021 - 10:02pm

The closing of the private placement is expected to occur on or about February 23, 2021, subject to satisfaction of customary closing conditions.

Key Points: 
  • The closing of the private placement is expected to occur on or about February 23, 2021, subject to satisfaction of customary closing conditions.
  • ReWalk Robotics Ltd. develops, manufactures, and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.
  • ReWalkis a registered trademark of ReWalk Robotics Ltd. in Israel and the United States.
  • ReStoreis a registered trademark of ReWalk Robotics Ltd. in Europe and an allowed trademark in the United States.

Ekso Bionics® to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Thursday, February 18, 2021 - 1:00pm

RICHMOND, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2020 after the close of trading on Thursday, February 25, 2021.

Key Points: 
  • RICHMOND, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2020 after the close of trading on Thursday, February 25, 2021.
  • ET to discuss the financial results and recent business developments.
  • Investors interested in listening to the conference call may do so by dialing 877-407-3036 for domestic callers or 201-378-4919 for international callers.
  • The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

ReWalk Robotics to Report Fourth Quarter 2020 Financial Results on February 18, 2021

Monday, February 15, 2021 - 5:44pm

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.

Key Points: 
  • ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.
  • ReWalks mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies.
  • Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.
  • ReWalk is a registered trademark of ReWalk Robotics Ltd. in Israel and the Unites States.

Ekso Bionics Announces Closing of $40 Million Bought Deal Offering

Thursday, February 11, 2021 - 9:35pm

RICHMOND, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (Ekso Bionics), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced underwritten public offering of 3,902,440 shares of common stock of Ekso Bionics, at a price to the public of $10.25 per share, less underwriting discounts and commissions.

Key Points: 
  • RICHMOND, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (Ekso Bionics), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced underwritten public offering of 3,902,440 shares of common stock of Ekso Bionics, at a price to the public of $10.25 per share, less underwriting discounts and commissions.
  • The gross proceeds to Ekso Bionics, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriters option to purchase additional common stock, are expected to be approximately $40.0 million.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.
  • To learn more about Ekso Bionics please visit Ekso Bionicss website at www.eksobionics.com or refer to Ekso Bionicss Twitter page at @EksoBionics.